Paion happy with CeNeS's morphine-6-glucuronide
This article was originally published in Scrip
German biotech company Paion has declared itself satisfied with a meta-analysis of Phase II and III data involving the potential intravenous analgesic product, morphine-6-glucuronide (M6G), which it acquired when it bought the UK firm, CeNeS Pharmaceuticals, in June.
You may also be interested in...
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.